Neuromuscular blocking agents: Difference between revisions

(Text replacement - "==Sources==" to "==References==")
 
(2 intermediate revisions by 2 users not shown)
Line 14: Line 14:
!Side effects
!Side effects
|-
|-
| '''Non-Depolarizing'''
| '''Depolarizing'''
|-
|-
|[[Succinylcholine]]
|[[Succinylcholine]]
Line 21: Line 21:
|fasciculations, post-operative pain  
|fasciculations, post-operative pain  
|-
|-
| '''Depolarizing'''
| '''Non-Depolarizing'''
|-
|-
|[[Vecuronium]] (Norcuron)
|[[Vecuronium]] (Norcuron)
Line 38: Line 38:
|
|
*[[tachycardia]] (slight)
*[[tachycardia]] (slight)
*(no hypotension)
*(no [[hypotension]])
|-
|-
|}
|}
==See Also==
*Reversal agent: [[Sugammadex]]


==References==
==References==
Line 46: Line 49:


[[Category:Pharmacology]]
[[Category:Pharmacology]]
[[Category:Critical Care]]

Latest revision as of 00:47, 25 February 2020

Background

  • Non-depolarizing
    • Competitively block binding of ACh to its receptors
  • Depolarizing
    • Depolarizing skeletal muscle fiber
    • Persistent depolarization makes the muscle fiber resistant to further stimulation by ACh

Types

Neuromuscular Blocking Agents
Agent Time to onset (seconds) Duration (minutes) Side effects
Depolarizing
Succinylcholine fasciculations, post-operative pain
Non-Depolarizing
Vecuronium (Norcuron) 60 30–40 Few, may cause prolonged paralysis and promote muscarinic block
Rocuronium (Zemuron) 75 45–70 may promote muscarinic block
Pancuronium (Pavulon) 90 180 or more

See Also

References